Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.

NCT06334185 | Not Yet Recruiting

• 1 other identifier: pVax
• Study Type: observational
• Target: 320
• Locations: 0 countries
• Sites: N/A

Brief Summary

Respiratory tract infections are among the leading causes of death worldwide and many of these infections are preventable through vaccination. One of the most important bacteria from an etiological and mortality point of view regarding respiratory and systemic infections is the gram-positive Streptococcus pneumoniae. Four types of vaccines are currently available for this pathogen: three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20) and one polysaccharide vaccine (PPSV23). In Italy, people over 65 years of age and people suffering from chronic pathologies with effects on the immune system would be advised to be vaccinated with the pneumococcal conjugate vaccine and with the polysaccharide vaccine as a second dose. However, there are no data available in Italy on vaccination coverage in these population categories and above all the vaccination rates in patients who have a history of an episode of invasive pneumococcal infection are not known. The aim of the study is to measure how many patients are vaccinated for S. pneumoniae after hospitalization for a systemic pneumococcal infection in order to understand patients' awareness of preventing this infection after receiving a first diagnosis.

Conditions

Invasive Pneumococcal Infection

Outcome Measures

Primary Outcomes (1)

• Rate of antipneumococcal vaccination in hospitalized patients for invasive pneumococcal infection between 2015 and 2019.

  The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.

Secondary Outcomes (1)

• Rate of pneumococcal serotype that caused the invasive infection in patients vaccinated prior to the infectious event

  The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A retrospective multicenter study is planned on patients admitted to the Alessandro Manzoni Hospital in Lecco and the San Raffaele Hospital in Milan with a diagnosis of systemic pneumococcal infection from 01/01/2015 to 12/31/2019 before the SARS pandemic -CoV-2. All patients admitted with a diagnosis of invasive pneumococcal infection defined by positive blood or CSF cultures for S. pneumoniae by the microbiology laboratory were enrolled.

You may qualify if:

• Patients over 18 years old;
• Patients hospitalized at the Manzoni Hospital in Lecco or at the San Raffaele Hospital in Milan with invasive pneumococcal infection in the period between 01/01/2015 and 31/12/2019;
• Presence of a positive culture test for S. pneumoniae on blood cultures and/or liquor;
• Patients whose discharge letter or clinical documentation relating to the infectious episode is available;
• Patients whose vaccination record can be consulted (on paper or on SIAVR) and whose vaccination history is available before and after hospitalization.

You may not qualify if:

• Patients with positive urinary antigen for S. pneumoniae as the only microbiological finding;
• Patients whose vaccination history or vaccination records are not available.

Sponsors & Collaborators

• Azienda Ospedaliera di Lecco: lead
• IRCCS Ospedale San Raffaele: collaborator

Study Officials

• Antonella Castagna, Prof

  IRCCS Ospedale San Raffaele Turro - Milano Infectious Diseases Unit

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Stefania Piconi, MD

CONTACT

0341-489890; s.piconi@asst-lecco.it

Silvia Pontiggia

CONTACT

0341-253678; s.pontiggia@asst-lecco.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Infectious Diseases Unit

Study Record Dates

• First Submitted: March 20, 2024
• First Posted: March 27, 2024
• Study Start: May 31, 2024
• Primary Completion: July 1, 2024
• Study Completion: July 1, 2024
• Last Updated: May 21, 2024

Record last verified: 2024-05